Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage

Katrina M.Mirabito Colafella*, Daan C.H. van Dorst, Rugina I. Neuman, Leni van Doorn, Karla Bianca Neves, Augusto C. Montezano, Ingrid M. Garrelds, Richard van Veghel, René de Vries, Estrellita Uijl, Marian C. Clahsen-Van Groningen, Hans J. Baelde, Anton H. van den Meiracker, Rhian M. Touyz, Willy Visser, A. H. Jan Danser, Jorie Versmissen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)
26 Downloads (Pure)

Abstract

Vascular endothelial growth factor antagonism with angiogenesis inhibitors in cancer patients induces a 'preeclampsia-like' syndrome including hypertension, proteinuria and elevated endothelin (ET)-1. Cyclo-oxygenase (COX) inhibition with aspirin is known to prevent the onset of preeclampsia in high-risk patients. In the present study, we hypothesised that treatment with aspirin would prevent the development of angiogenesis inhibitor-induced hypertension and kidney damage. Our aims were to compare the effects of low-dose (COX-1 inhibition) and high-dose (dual COX-1 and COX-2 inhibition) aspirin on blood pressure, vascular function, oxidative stress, ET-1 and prostanoid levels and kidney damage during angiogenesis-inhibitor therapy in rodents. To this end, Wistar Kyoto rats were treated with vehicle, angiogenesis inhibitor (sunitinib) alone or in combination with low- or high-dose aspirin for 8 days (n=5-7/group). Our results demonstrated that prostacyclin (PGI2) and ET-1 were increased during angiogenesis-inhibitor therapy, while thromboxane (TXA2) was unchanged. Both low- and high-dose aspirin blunted angiogenesis inhibitor-induced hypertension and vascular superoxide production to a similar extent, whereas only high-dose aspirin prevented albuminuria. While circulating TXA2 and prostaglandin F2α levels were reduced by both low- and high-dose aspirin, circulating and urinary levels PGI2 were only reduced by high-dose aspirin. Lastly, treatment with aspirin did not significantly affect ET-1 or vascular function. Collectively our findings suggest that prostanoids contribute to the development of angiogenesis inhibitor-induced hypertension and renal damage and that targeting the prostanoid pathway could be an effective strategy to mitigate the unwanted cardiovascular and renal toxicities associated with angiogenesis inhibitors.

Original languageEnglish
Pages (from-to)675-694
Number of pages20
JournalClinical Science
Volume136
Issue number9
DOIs
Publication statusPublished - 10 May 2022

Bibliographical note

Funding Information:
This work was supported by the National Health and Medical Research Council (NHMRC) of Australia CJ Martin Fellowship [grant number GNT1112125 (to Katrina M. Mirabito Colafella)]; the Foundation Lijf en Leven (to A. H. Jan Danser and Anton H. van den Meiracker); the British Heart Foundation [grant numbers RE/18/6/34217, CH/12/4/29762 (to Rhian M. Touyz)]; and the Walton Fellowship from the University of Glasgow (to Augusto C. Montezano).

Publisher Copyright: © 2022 The Author(s).

Fingerprint

Dive into the research topics of 'Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage'. Together they form a unique fingerprint.

Cite this